 |
|
Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs
Soo-Young Na, You Sun Kim
Korean J Intern Med. 2022;37(5):906-919. Published online 2022 Aug 10 DOI: https://doi.org/10.3904/kjim.2022.152
|
|
Citations to this article as recorded by
 Gentianopsis paludosa Regulates TL1A/DR3 and ZNF281 to Affect Inflammatory Bowel Disease-Associated Intestinal Fibrosis
Zhao Huiqiao, Lu Nianhua, Zhang Yongpeng, Jin Guoyin, He Wei
International Journal of Pharmacology.2024; 20(4): 642. CrossRef Dopamine β-hydroxylase shapes intestinal inflammation through modulating T cell activation
Qiaoling Sun, Heng Li, Jing Lv, Weilin Shi, Yanfeng Bai, Ke Pan, Alice Chen
Cellular Immunology.2024; 401-402: 104839. CrossRef Meta-analysis of etrolizumab versus placebo in ulcerative colitis: safety and efficacy outcomes
Rui Zhang, Ziran Jia, Yingshi Piao
Therapeutic Advances in Gastroenterology.2024;[Epub] CrossRef Treatment of primary sclerosing cholangitis combined with inflammatory bowel disease
You Sun Kim, Edward H. Hurley, Yoojeong Park, Sungjin Ko
Intestinal Research.2023; 21(4): 420. CrossRef
|